UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144 Filer Information

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001020741

Filer CCC XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer Veracyte, Inc. SEC File Number 001-36156

6000 Shoreline Court

Suite 300

Address of Issuer South San Francisco

CALIFORNIA

94080

Phone 1-650-243-6300

Name of Person for Whose Account the Securities are To Be Sold jVen Capital, LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			SACHIPITIAG
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	7441	221592.98	72417156	07/18/2023	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *

Transaction	Whom Acquired	a Acquired Gift?	Acquired	
Acquired from Common Stock 07/26/2011 issuer in private transaction	Veracyte, Inc. (Issuer)		7441	07/26/2011 Cash

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
jVen Capital, LLC 6000 Shoreline Court Suite 300 South San Francisco CA 94080	Common Stock	07/17/2023	23949	720105.72
Evan Jones 6000 Shoreline Court Suite 300 South San Francisco, CA, 94080	Common Stock	07/17/2023	19095	574106.45

144: Remarks and Signature

The sales of shares set forth herein are made in connection with a selling plan dated Remarks 12/12/2022, that is intended to comply with Rule 10b5-1(c). All shares sold by jVen

Capital, LLC.

Date of Notice 07/18/2023

Date of Plan Adoption or Giving of

Instruction, If Relying on Rule 10b5-1

12/12/2022

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Goldman Sachs & Co. LLC on behalf of Evan Jones

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)